158 related articles for article (PubMed ID: 37591861)
1. The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain.
Minderman M; Lantermans H; van der Zwaan C; Hoogendijk AJ; van den Biggelaar M; Kersten MJ; Spaargaren M; Pals ST
Blood Cancer J; 2023 Aug; 13(1):125. PubMed ID: 37591861
[TBL] [Abstract][Full Text] [Related]
2. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
3. Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.
Turi M; Anilkumar Sithara A; Hofmanová L; Žihala D; Radhakrishnan D; Vdovin A; Knápková S; Ševčíková T; Chyra Z; Jelínek T; Šimíček M; Gullà A; Anderson KC; Hájek R; Hrdinka M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982699
[TBL] [Abstract][Full Text] [Related]
4. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis identifies residues crucial for homodimerization of myeloid differentiation factor 88 (MyD88) and for its function in immune cells.
Loiarro M; Volpe E; Ruggiero V; Gallo G; Furlan R; Maiorino C; Battistini L; Sette C
J Biol Chem; 2013 Oct; 288(42):30210-30222. PubMed ID: 24019529
[TBL] [Abstract][Full Text] [Related]
6. MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis.
Yu X; Li W; Deng Q; Liu H; Wang X; Hu H; Cao Y; Xu-Monette ZY; Li L; Zhang M; Lu Z; Young KH; Li Y
Blood; 2021 Mar; 137(12):1615-1627. PubMed ID: 33025009
[TBL] [Abstract][Full Text] [Related]
7. MYD88 L265P mutation in Waldenstrom macroglobulinemia.
Poulain S; Roumier C; Decambron A; Renneville A; Herbaux C; Bertrand E; Tricot S; Daudignon A; Galiègue-Zouitina S; Soenen V; Theisen O; Grardel N; Nibourel O; Roche-Lestienne C; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
Blood; 2013 May; 121(22):4504-11. PubMed ID: 23532735
[TBL] [Abstract][Full Text] [Related]
8. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
Choi JW; Kim Y; Lee JH; Kim YS
Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.
Seltzer J; Moorad R; Schifano JM; Landis JT; Dittmer DP
J Virol; 2020 May; 94(10):. PubMed ID: 32161170
[TBL] [Abstract][Full Text] [Related]
10. Conformational dynamics of cancer-associated MyD88-TIR domain mutant L252P (L265P) allosterically tilts the landscape toward homo-dimerization.
Zhan C; Qi R; Wei G; Guven-Maiorov E; Nussinov R; Ma B
Protein Eng Des Sel; 2016 Sep; 29(9):347-54. PubMed ID: 27503954
[TBL] [Abstract][Full Text] [Related]
11. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G
Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863
[TBL] [Abstract][Full Text] [Related]
12. [MyD88 L265P mutation and B cell tumor].
Chen HM; Hou J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):241-4. PubMed ID: 24598687
[TBL] [Abstract][Full Text] [Related]
13. Absence of Non-Canonical, Inhibitory
Cardona Gloria Y; Bernhart SH; Fillinger S; Wolz OO; Dickhöfer S; Admard J; Ossowski S; Nahnsen S; Siebert R; Weber ANR
Front Immunol; 2021; 12():616451. PubMed ID: 34163463
[TBL] [Abstract][Full Text] [Related]
14. MYD88 L265P mutation promoted malignant B cell resistance against T cell-mediated cytotoxicity via upregulating the IL-10/STAT3 cascade.
Qiu H; Gong S; Xu L; Cheng H; Gao L; Chen J; Hu X; Yang J
Int Immunopharmacol; 2018 Nov; 64():394-400. PubMed ID: 30253331
[TBL] [Abstract][Full Text] [Related]
15. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
[TBL] [Abstract][Full Text] [Related]
16. Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance.
Wang JQ; Jeelall YS; Beutler B; Horikawa K; Goodnow CC
J Exp Med; 2014 Mar; 211(3):413-26. PubMed ID: 24534189
[TBL] [Abstract][Full Text] [Related]
17. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
[No Abstract] [Full Text] [Related]
18. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
Yamada S; Ishida Y; Matsuno A; Yamazaki K
Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427
[TBL] [Abstract][Full Text] [Related]
19. Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization.
Avbelj M; Wolz OO; Fekonja O; Benčina M; Repič M; Mavri J; Krüger J; Schärfe C; Delmiro Garcia M; Panter G; Kohlbacher O; Weber AN; Jerala R
Blood; 2014 Dec; 124(26):3896-904. PubMed ID: 25359991
[TBL] [Abstract][Full Text] [Related]
20. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
